October 4, 2018 Regulatory AcuCort obtains regulatory approval to start bioequivalence study for the EU
September 7, 2018 Regulatory AcuCort’s allergy medicine Dexa ODF has been manufactured and released according to Good Manufacturing Practice, GMP
June 21, 2018 Regulatory AcuCort signs agreement with the CRO Quinta-Analytica concerning the performance of bioequivalence studies
June 12, 2018 Regulatory AcuCort’s allergy treatment Dexa ODF is ready to be manufactured according to GMP (Good Manufacturing Practice) for clinical use
April 24, 2018 Regulatory Correction and clarification concerning the expiry dates of AcuCort’s patents
April 16, 2018 Regulatory AcuCort’s patent is granted with 1,349 days extended patent protection in the US